Strategic Partnerships Kent Imaging is expanding distribution and integration capabilities, evidenced by the December 2025 partnership with New Horizon Medical Solutions and the June 2026 Epic integration for SnapshotNIR. Sales opportunities exist in channel partnerships and EHR/EMR interoperability projects to broaden adoption and streamline clinical workflows.

Product Portfolio The SnapshotNIR and SnapshotGLO product duo offers complementary capabilities for tissue oxygenation imaging and bioburden detection. This creates cross-sell opportunities within wound care, vascular, and surgical markets, especially in clinics seeking real-time decision support and infection control enhancements.

Regulatory Momentum Recent regulatory clearances and CE-mark updates, with SnapshotNIR CE-marked in 2025 and SnapshotGLO FDA 510(k) clearance in 2025, indicate a growing global market access trajectory. Target customers in regulated markets and hospital systems prioritizing compliant, traceable imaging solutions.

Clinical Validation Clinical evidence supports SnapshotNIR’s impact on decision-making and SnapshotGLO’s bioburden insight. Opportunities exist to engage case studies and key opinion leaders to accelerate pilot programs, deployment in wound care pathways, and payer discussions around value-based outcomes.

Growth Financing With ongoing funding activity including a planned Series B and previous investments, Kent Imaging has capital to scale sales, expand installation capacity, and broaden international reach. Target multi-site health systems and distributors that can leverage new capital to accelerate adoption.